Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cenerimod in Moderate to Severe Systemic Lupus Erythematosus (SLE)
NCT03742037Phase 2Completed
- Sponsor
- Viatris
- Start
- Dec 2018
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 24
01
Overview
Phase 2, randomised, double-blind trial of cenerimod in systemic lupus erythematosus (SLE) (7 arms), sponsored by Viatris. Primary endpoint: Modified Systemic Lupus Erythematosus Activity Index 2000 Score at 6 months. Started Dec 2018; status: completed.
02
Drugs
cenerimod
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT03742037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03742037.